Developer docs
API playgroundTry for free, no card

Search company profiles

Dolon

Full company profile

uuid000fgcb

Namestring
Dolon
Legal namestring
Dolon Ltd
Websiteurl
dolon.com
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
market access consulting, pharmaceutical pricing strategy, rare disease consulting, oncology market access, health technology assessment
NAICS code2 codes
  • Management Consulting Services54161
  • Professional, Scientific, and Technical Services54
Product category
Pharmaceutical Market Access Consulting
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Consulting Services
TypeProfessional Services
Description

Dolon generates revenue by providing strategic consulting services to biopharma clients, including market access strategy, pricing strategy, value development, and policy advisory across the drug lifecycle. Engagements are project-based and consultative in nature.

dolon.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Dolon is an independent consultancy specializing in strategic pricing and market access for pharmaceutical and biotechnology companies developing rare disease and oncology medicines. The firm delivers five integrated service lines — Value, Access, Pricing, Market Access Policy, and Data & Analytics — through bespoke, project-based engagements that turn complex clinical and reimbursement landscapes into actionable strategies. Following its March 2026 acquisition by Prescient Healthcare Group, Dolon operates as a dedicated Value, Pricing and Access practice serving biopharma clients globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 97% of projects delivered in rare diseases and oncology, with 12+ years of experience and 1,000+ successful engagements
+1 more record
Product overview1 text field

Dolon is a strategic pricing and market access consultancy, not a software product company. The company offers five integrated consulting service lines: Value, Access, Pricing, Market Access Policy, and Data & Analytics. These services are delivered by specialist consultants to help pharmaceutical and biotechnology companies navigate market access challenges for rare disease and oncology medicines. Following its acquisition by Prescient Healthcare Group in March 2026, Dolon operates as a dedicated Value, Pricing and Access practice within the Prescient organization.

Product and service5 records
1Value
CategoryStrategic Consulting
Description

Strategic value development service that turns complex clinical and evidence landscapes into high-impact value strategies, bridging clinical promise and reimbursement reality for rare disease and oncology medicines. Targeted at pharmaceutical and biotechnology companies seeking evidence-based value narratives.

2Access
CategoryStrategic Consulting
Description

Global payer pathway advisory service that guides biopharma clients through access environments to ensure launch readiness and deliver treatments to patients who need them. Focused on rare disease and oncology launches.

3Pricing
CategoryStrategic Consulting
Description

Pricing strategy consulting service that helps biopharma clients navigate pricing complexity with confidence, crafting robust and communicable price strategies credible from the boardroom to the negotiating table, focused on rare disease and oncology products.

4Market Access Policy
CategoryStrategic Consulting
Description

Market access policy advisory that identifies policy imperatives for client portfolios and helps build compelling evidence, credible payer proposals, and stakeholder engagement strategies to drive positive access policy change within existing regulatory and reimbursement frameworks.

5Data & Analytics
CategoryStrategic Consulting
Description

Data and analytics consulting service that turns data into decisions through advanced bespoke models, internal databases, and proprietary tools to define direction and influence outcomes for rare disease and oncology clients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Prescient Healthcare Group acquired Dolon on 30 March 2026. Dolon will retain its specialist focus, joining as a dedicated Value, Pricing and Access practice working alongside Prescient's established teams. The partnership delivers seamless, comprehensive support for complex challenges, ensuring vital strategic pricing and market access insights inform pivotal decisions earlier and further across the product lifecycle. This follows Prescient's earlier acquisition of Uptake Strategies and is backed by investor Bridgepoint.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Squire Patton Boggs served as legal advisor to Dolon and its shareholders in connection with the acquisition by Prescient Healthcare Group.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A boutique consultancy serving biopharma on commercial strategy, market access, and pricing. Closely aligned with Dolon in size, therapeutic-area focus, and bespoke service model for pharmaceutical and biotech clients.

TypeBroad incumbent
Description

A global life sciences services and data platform that includes pricing, market access, and HEOR consulting alongside its broader commercial and R&D offerings. Comparable to Dolon in service categories, but operates at vastly greater scale and with a technology/data-led model.

TypeDirect peer
Description

A global consulting firm with a strong life sciences pricing and market access practice. Directly comparable to Dolon in pricing strategy and value-based commercialization work, though with materially broader geographic and industry coverage.

TypeBroad incumbent
Description

A HEOR, market access, and real-world evidence consultancy serving biopharma. Comparable to Dolon in access and evidence work, but operating as part of a large CRO platform with broader R&D and data services.

TypeBroad incumbent
Description

A global consulting firm with a Life Sciences practice providing pricing, market access, and commercial strategy support to biopharma. Comparable to Dolon in service overlap, but a significantly larger and more diversified practice across industries.

TypeDirect peer
Description

A boutique life sciences strategy consultancy providing market access, pricing, and commercial insights to biopharma. Directly comparable to Dolon in therapeutic-area focus, specialist positioning, and bespoke delivery model.

TypeDirect peer
Description

A specialist consulting firm focused on biopharma pricing, market access, and commercial strategy. Directly comparable to Dolon in service scope (pricing, access, value) and biopharma client base, with similar boutique positioning.

TypeBroad incumbent
Description

A global management consultancy with a large Pharma & Medical Products practice delivering pricing, market access, and commercial strategy work. Overlaps with Dolon at the high end of pharma pricing and access engagements, but as a generalist powerhouse with vastly greater resources.

TypeDirect peer
Description

A life sciences strategy and insights consultancy offering market access, pricing, evidence, and commercial services to biopharma. Closely comparable to Dolon in therapeutic-area depth, pricing and access advisory, and project-based delivery model, though considerably larger in scale.

10ZS Associates
TypeBroad incumbent
Description

A large global consulting firm with a deep pharma and biotech practice spanning commercial, pricing, market access, and data analytics. Overlaps with Dolon in pricing and access advisory but operates at a much larger scale and with proprietary analytics platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dolon

Pharmaceutical Market Access Consultingdolon.com

Dolon firmographics

Firmographics
Name
Dolon
Legal name
Dolon Ltd
Website
https://dolon.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
51–100 employees
Ownership category
akta.pro rank

Where Dolon is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Dolon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Strategic Consulting Services: Dolon generates revenue by providing strategic consulting services to biopharma clients, including market access strategy, pricing strategy, value development, and policy advisory across the drug lifecycle. Engagements are project-based and consultative in nature.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Dolon product offering

Product offering

Core offering

Dolon is an independent consultancy specializing in strategic pricing and market access for pharmaceutical and biotechnology companies developing rare disease and oncology medicines. The firm delivers five integrated service lines — Value, Access, Pricing, Market Access Policy, and Data & Analytics — through bespoke, project-based engagements that turn complex clinical and reimbursement landscapes into actionable strategies. Following its March 2026 acquisition by Prescient Healthcare Group, Dolon operates as a dedicated Value, Pricing and Access practice serving biopharma clients globally.

Product overview

Dolon is a strategic pricing and market access consultancy, not a software product company. The company offers five integrated consulting service lines: Value, Access, Pricing, Market Access Policy, and Data & Analytics. These services are delivered by specialist consultants to help pharmaceutical and biotechnology companies navigate market access challenges for rare disease and oncology medicines. Following its acquisition by Prescient Healthcare Group in March 2026, Dolon operates as a dedicated Value, Pricing and Access practice within the Prescient organization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Value Strategic value development service that turns complex clinical and evidence landscapes into high-impact value strategies, bridging clinical promise and reimbursement reality for rare disease and oncology medicines. Targeted at pharmaceutical and biotechnology companies seeking evidence-based value narratives.
  • Access Global payer pathway advisory service that guides biopharma clients through access environments to ensure launch readiness and deliver treatments to patients who need them. Focused on rare disease and oncology launches.
  • Pricing Pricing strategy consulting service that helps biopharma clients navigate pricing complexity with confidence, crafting robust and communicable price strategies credible from the boardroom to the negotiating table, focused on rare disease and oncology products.
  • Market Access Policy Market access policy advisory that identifies policy imperatives for client portfolios and helps build compelling evidence, credible payer proposals, and stakeholder engagement strategies to drive positive access policy change within existing regulatory and reimbursement frameworks.
  • Data & Analytics Data and analytics consulting service that turns data into decisions through advanced bespoke models, internal databases, and proprietary tools to define direction and influence outcomes for rare disease and oncology clients.

Quantifiable outcome

  • 97% of projects delivered in rare diseases and oncology, with 12+ years of experience and 1,000+ successful engagements
  • +1 more outcomes

Companies that use Dolon

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Dolon technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Dolon partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Prescient Healthcare GroupcoreStrategic or Co-development Partner · 30 March 2026Prescient Healthcare Group acquired Dolon on 30 March 2026. Dolon will retain its specialist focus, joining as a dedicated Value, Pricing and Access practice working alongside Prescient's established teams. The partnership delivers seamless, comprehensive support for complex challenges, ensuring vital strategic pricing and market access insights inform pivotal decisions earlier and further across the product lifecycle. This follows Prescient's earlier acquisition of Uptake Strategies and is backed by investor Bridgepoint.
  • Squire Patton BoggsminorImplementation/ SI/ Consulting PartnerSquire Patton Boggs served as legal advisor to Dolon and its shareholders in connection with the acquisition by Prescient Healthcare Group.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Dolon competitors and assessment

Company assessment

Direct peers

  • LSC Life Sciences Consulting: A boutique consultancy serving biopharma on commercial strategy, market access, and pricing. Closely aligned with Dolon in size, therapeutic-area focus, and bespoke service model for pharmaceutical and biotech clients.
  • Simon-Kucher & Partners: A global consulting firm with a strong life sciences pricing and market access practice. Directly comparable to Dolon in pricing strategy and value-based commercialization work, though with materially broader geographic and industry coverage.
  • ClearView Healthcare Partners: A boutique life sciences strategy consultancy providing market access, pricing, and commercial insights to biopharma. Directly comparable to Dolon in therapeutic-area focus, specialist positioning, and bespoke delivery model.
  • Putnam Associates: A specialist consulting firm focused on biopharma pricing, market access, and commercial strategy. Directly comparable to Dolon in service scope (pricing, access, value) and biopharma client base, with similar boutique positioning.
  • Trinity Life Sciences: A life sciences strategy and insights consultancy offering market access, pricing, evidence, and commercial services to biopharma. Closely comparable to Dolon in therapeutic-area depth, pricing and access advisory, and project-based delivery model, though considerably larger in scale.

Broad incumbents

  • IQVIA: A global life sciences services and data platform that includes pricing, market access, and HEOR consulting alongside its broader commercial and R&D offerings. Comparable to Dolon in service categories, but operates at vastly greater scale and with a technology/data-led model.
  • Evidera (PPD / Thermo Fisher Scientific): A HEOR, market access, and real-world evidence consultancy serving biopharma. Comparable to Dolon in access and evidence work, but operating as part of a large CRO platform with broader R&D and data services.
  • Charles River Associates (CRA): A global consulting firm with a Life Sciences practice providing pricing, market access, and commercial strategy support to biopharma. Comparable to Dolon in service overlap, but a significantly larger and more diversified practice across industries.
  • McKinsey & Company (Pharma & Medical Products): A global management consultancy with a large Pharma & Medical Products practice delivering pricing, market access, and commercial strategy work. Overlaps with Dolon at the high end of pharma pricing and access engagements, but as a generalist powerhouse with vastly greater resources.
  • ZS Associates: A large global consulting firm with a deep pharma and biotech practice spanning commercial, pricing, market access, and data analytics. Overlaps with Dolon in pricing and access advisory but operates at a much larger scale and with proprietary analytics platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Dolon social profiles

Digital presence

Dolon compliance and trust

Trust signal

Compliance1 record

Dolon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dolon leadership team

Management profile

Number of profiles

Dolon funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dolon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dolon

What does Dolon do?

Dolon is an independent consultancy specializing in strategic pricing and market access for pharmaceutical and biotechnology companies developing rare disease and oncology medicines. The firm delivers five integrated service lines — Value, Access, Pricing, Market Access Policy, and Data & Analytics — through bespoke, project-based engagements that turn complex clinical and reimbursement landscapes into actionable strategies. Following its March 2026 acquisition by Prescient Healthcare Group, Dolon operates as a dedicated Value, Pricing and Access practice serving biopharma clients globally.

Is Dolon a public or private company?

Dolon is a private company. It is classified as corporate owned and is currently acquired.

When was Dolon founded?

Dolon was founded in 2013. It employs 51 to 100 people.

Where is Dolon based?

Dolon is headquartered in London, United Kingdom, in the Europe region.

How does Dolon make money?

One revenue line is on record: strategic Consulting Services.

Who are Dolon's main competitors?

Direct peers on record are LSC Life Sciences Consulting, Simon-Kucher & Partners, ClearView Healthcare Partners, Putnam Associates and Trinity Life Sciences. Broad incumbents are IQVIA, Evidera (PPD / Thermo Fisher Scientific), Charles River Associates (CRA), McKinsey & Company (Pharma & Medical Products) and ZS Associates.

Does Dolon have an API?

No public API is recorded for Dolon.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Prescient Healthcare Acquires Dolon To Expand Pricing And Market Access Capabilities Across Drug LifecyclePrescient Healthcare Group has acquired Dolon, a London-based consultancy specializing in strategic pricing and market access for the pharmaceutical and biotechnology industries. The transaction, supported by private equity firm Bridgepoint, follows Prescient's earlier purchase of Uptake Strategies this year and represents another step in its broader growth strategy to expand its global platform and U.S. presence. Dolon will continue operating as a dedicated Value, Pricing, and Access practice within Prescient, combining capabilities to provide integrated support across the product lifecycle for biopharma clients.Business Wire BlogPrescient Acquires Dolon, to Enhance Its Strategic Pricing and Market Access Capabilities and Expertise Across the Drug Lifecycle.Prescient (Prescient Healthcare Group) has acquired London-based pricing and market access consultancy Dolon, strengthening its capabilities to support global biopharma companies navigating complex clinical, commercial, and market access environments. Dolon will retain its specialist focus as a dedicated Value, Pricing and Access practice working alongside Prescient's existing teams, with the partnership delivering comprehensive support across the product lifecycle. The transaction, backed by existing investor Bridgepoint, follows Prescient's earlier acquisition of Uptake Strategies earlier this year and reflects the company's continued growth strategy.PrescienthgPrescient acquires Dolon, to enhance its strategic pricing and market access capabilities and expertise across the drug lifecyclePrescient Healthcare Group has acquired London-based consultancy Dolon, a strategic pricing and market access firm specializing in rare diseases and oncology, strengthening Prescient's ability to support global biopharma companies across complex clinical, commercial, and market access environments. The acquisition, with undisclosed financial terms and backed by investor Bridgepoint, will integrate Dolon as a dedicated Value, Pricing and Access practice operating alongside Prescient's established teams. This move follows Prescient's earlier acquisition of Uptake Strategies and represents continued purposeful growth, enabling clients to receive comprehensive lifecycle support informed by strategic pricing and market access insights earlier in the product development process.